A retrospective study evaluating overall response rate and other outcomes related to originator and biosimilar rituximabin patients with chronic lymphocytic leukemia or non-Hodgkin's lymphoma in the United Kingdom
Latest Information Update: 21 Jul 2021
At a glance
- Drugs Rituximab (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 21 Jul 2021 New trial record